Zum Inhalt
Erschienen in:

22.08.2017 | short review

New chemotherapies in breast cancer

verfasst von: Matthias Ranftler, MD, Kathrin Strasser-Weippl, MD, MBA

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Summary

In the era of targeted therapies and immunotherapy for cancer, the focus in breast cancer (BC) research has shifted away from classical chemotherapy. Many BC patients, however, still need chemotherapy and thus benefit from the development of new chemotherapeutic agents or regimens. In the past decade, the approval of eribulin and trastuzumab emtansine (T-DM1) have been important advances in this regard. Improved ways of delivery of paclitaxel, anthracyclines, and vinorelbine have also had a considerable clinical impact. Finally, optimizing the use of well-known drugs, such as carboplatin, capecitabine, or adjuvant chemoimmunotherapy in low-risk early BC, has brought about progress in the field of chemo(immuno)therapy.
Literatur
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
Metadaten
Titel
New chemotherapies in breast cancer
verfasst von
Matthias Ranftler, MD
Kathrin Strasser-Weippl, MD, MBA
Publikationsdatum
22.08.2017
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2017
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-017-0348-y